Indication intelligence, analysis and sector perception

BioTime (NYSE MKT and TASE: BTX) has appointed Russell Skibsted to the position of CFO succeeding Robert Peabody

March 15, 2016 2:13pm

Robert Peabody is joining another subsidiary, LifeMap Solutions to apply his early stage expertise in assisting the company on its business strategy, vision, and equity capital raising among other activities.

Mr. Russell Skibsted brings over 25 years of financial management and life sciences business experience to BioTime. He has served as CFO for both public and private life sciences companies. Immediately prior to joining the BioTime team, Russell was CFO at Proove Biosciences, a commercial-stage diagnostics and personalized medicine company. Previously he was Senior Vice President, CFO, and Secretary of Aeolus Pharmaceuticals, a biotechnology company that received over $150M in government funding in the biodefense and oncology sectors. Mr. Skibsted also served as SVP and Chief Business Officer of Spectrum Pharmaceuticals, a commercial-stage pharmaceutical company, and as CFO of Hana Biosciences. During his tenure at these companies, Mr. Skibsted successfully raised several investment rounds, including both public and private offerings as well as corporate partnerships, while raising the profile of these companies and developing strong relationships with institutional investors and analysts. Earlier in his career, Mr. Skibsted was Partner and CFO at Asset Management Company. Mr. Skibsted holds an MBA from the Stanford Graduate School of Business, and a BA from Claremont McKenna College.

Robert W. Peabody has served as BioTime’s CFO since he joined the company in 2007. Working with co-CEO Dr. Michael West, he has helped BioTime to acquire and develop leading regenerative medicine assets, including both products under development and a large patent estate, thereby successfully repositioning the company to have multiple clinical-stage programs and leadership of the pluripotent stem cell field. Mr. Peabody has been instrumental in the development of several early stage companies, having been a co-founder of both Geron and Ocata Therapeutics, and having helped to create Asterias Therapeutics.

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

7 hours 52 min ago
RegMed Investors’ (RMi) pre-open: head and knee down

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.